
News|Podcasts|August 21, 2023
Pharmacy Focus: Oncology Edition - PARP Inhibitors Are Changing the Game in Prostate Cancer
This month, we spoke with Cassia Griswold, PharmD, a clinical oncology pharmacist at Mayo Clinic Arizona.
Advertisement
This month, we spoke with Cassia Griswold, PharmD, a clinical oncology pharmacist at Mayo Clinic Arizona. Griswold discussed the latest updates from ASCO in PARP inhibitors for prostate cancer, as well as what's on the horizon in this quickly-evolving treatment space.
Interested in learning more? Check out this related content:
FDA Approves New Combination Therapy for BRCA-Positive Metastatic Castration-Resistant Prostate Cancer Image-Guided Adaptive Radiation Treatments May Reduce Short-Term Adverse Effects in Patients With Prostate Cancer Compared to Non-Adaptive Treatments Enzalutamide Combination, Monotherapy Reduced the Risk of Metastasis or Death in High-Risk Patients With Prostate Cancer
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Updated 2025-2026 COVID-19 Vaccine Nearly Halved ED Visits, Hospitalizations in CDC-Funded Study
2
The Biosimilar Conversation Nobody Is Having at the Pharmacy Counter: Why Adoption Is Still Struggling and What We Can Do About It
3
FDA Scrutiny of GLP-1 Compounding Is Just Getting Started, Expert Says
4
Medicare Is Finally Covering GLP-1s for Weight Loss: What the Bridge Program Means for Your Practice
5


















































































































